Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for vTv Therapeutics (VTVT) over the last 10 years, with Dec 2024 value amounting to $3.2 million.

  • vTv Therapeutics' Shares Outstanding (Weighted Average) rose 0.16% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 0.16%. This contributed to the annual value of $3.2 million for FY2024, which is 22.00% up from last year.
  • Latest data reveals that vTv Therapeutics reported Shares Outstanding (Weighted Average) of $3.2 million as of FY2024, which was up 22.00% from $2.6 million recorded in FY2023.
  • vTv Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $3.2 million for FY2024, and its period low was $1.8 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $2.6 million (2023), whereas its average is $2.8 million.
  • Data for vTv Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 23.33% (in 2020) over the last 5 years.
  • Over the past 5 years, vTv Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $1.8 million in 2020, then grew by 21.87% to $2.3 million in 2021, then rose by 16.15% to $2.6 million in 2022, then remained steady at $2.6 million in 2023, then increased by 22.00% to $3.2 million in 2024.